



CLBB News

A newsletter from the Center for Law, Brain & Behavior

Online Event this Monday! **Detecting Dementia: Technology, Access, and the Law**

Click [Here](#) to Register

Detecting Dementia: Technology, Access, and the Law
November 16, 2020, 12:00-1:00 PM EDT

Advances in neuroimaging, genetics, and mobile health apps are creating unprecedented opportunities to detect subtle brain changes that may predict the onset of Alzheimer's disease and other types of dementia. But how much trust should we have in these new technologies, who will have access to them, and how should the law respond when litigants proffer novel evidence of their brain states? This panel will explore technological innovations in dementia detection, and their ethical, social, and legal implications.

In light of the COVID-19 pandemic, this panel discussion will be held virtually, as an online webinar. To ensure that you will receive access to the livestream and be kept up to date on any changes to the event, [register now](#). We will send out a link to the livestream of the event to all registrants the day before the event.

Detecting Dementia

Technology, Aging Brains, and the Law



Jonathan Jackson, PhD
Founding Director, Community Access, Recruitment and Engagement (CARE) Research Center at Massachusetts General Hospital and Harvard Medical School



Bruce H. Price, MD
Co-Founder and Co-Director, Massachusetts General Hospital Center for Law, Brain and Behavior
Associate Professor of Neurology, Harvard Medical School
Chief of Department of Neurology, McLean Hospital



Ipsit Vahia, MD
Medical Director, Geriatric Psychiatry Outpatient Services and McLean Institute for Technology in Psychiatry
Assistant Professor of Psychiatry, Harvard Medical School
PI, Technology in Aging Lab, McLean Hospital



Carmel Shachar, JD, MPH
Executive Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
Co-Lead, Regulatory Foundations, Ethics, and Law Program of Harvard Catalyst, Harvard Clinical and Translational Science Center



Advances in neuroimaging, genetics, and mobile health apps are creating unprecedented opportunities to detect subtle brain changes that may predict the onset of Alzheimer's disease and other types of dementia. But how much trust should we have in these new technologies, who will have access to them, and how should the law respond when litigants proffer novel evidence of their brain states? This panel will explore technological innovations in dementia detection, and their ethical, social, and legal implications.



Part of the Project on Law and Applied Neuroscience, a collaboration between the Center for Law, Brain & Behavior at Massachusetts General Hospital and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School



CENTER FOR LAW, BRAIN & BEHAVIOR



clbb.mgh.harvard.edu

MGH Center for Law, Brain & Behavior, Dept. of Psychiatry, Bulfinch 351,
55 Fruit St., Boston, MA 02114

[SafeUnsubscribe™ {recipient's email}](#).

[Forward this email](#) | [Update Profile](#) | [Customer Contact Data Notice](#)

Sent by contact@clbb.org powered by



Try email marketing for free today!